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Abstract
Background: MEK1/2 is a serine/threonine protein that phosphorylates extracellular signal-
regulated kinase (ERK1/2). Cerebral ischemia results in enhanced expression of cerebrovascular
contractile receptors in the middle cerebral artery (MCA) leading to the ischemic region. Here we
explored the role of the MEK/ERK pathway in receptor expression following ischemic brain injury
using the specific MEK1 inhibitor U0126.
Methods and result: Rats were subjected to a 2-h middle cerebral artery occlusion (MCAO)
followed by reperfusion for 48-h and the ischemic area was calculated. The expression of
phosphorylated ERK1/2 and Elk-1, and of endothelin ETA and ETB, angiotensin AT1, and 5-
hydroxytryptamine 5-HT1B receptors were analyzed with immunohistochemistry using confocal
microscopy in cerebral arteries, microvessels and in brain tissue. The expression of endothelin ETB
receptor was analyzed by quantitative Western blot. We demonstrate that there is an increase in
the number of contractile smooth muscle receptors in the MCA and in micro- vessels within the
ischemic region. The enhanced expression occurs in the smooth muscle cells as verified by co-
localization studies. This receptor upregulation is furthermore associated with enhanced
expression of pERK1/2 and of transcription factor pElk-1 in the vascular smooth muscle cells.
Blockade of transcription with the MEK1 inhibitor U0126, given at the onset of reperfusion or as
late as 6 hours after the insult, reduced transcription (pERK1/2 and pElk-1), the enhanced vascular
receptor expression, and attenuated the cerebral infarct and improved neurology score.
Conclusion: Our results show that MCAO results in upregulation of cerebrovascular ETB, AT1
and 5-HT1B receptors. Blockade of this event with a MEK1 inhibitor as late as 6 h after the insult
reduced the enhanced vascular receptor expression and the associated cerebral infarction.
Background
Acute focal cerebral ischemia results in a severely ischemic
core with low residual cerebral blood flow (CBF) whereas
the ischemic penumbra synaptic activity is reduced while
the residual CBF is enough to maintain membrane ionic
gradients. The expansion of depolarized core coincides
with the occurrence of spontaneous peri-infarct spreading
depolarization [1]. The tissue viability threshold and its
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and membrane failure in brain tissue [2,3], and therefore,
it has been suggested that the ischemic depolarization
increases the metabolic burden, thereby exacerbates the
energy deficit, and enlarges the infarct [4]. This view has
by and large neglected the fact that stroke primarily is a
cerebrovascular disorder. Recently, Shin and colleagues
presented data that there is neurovascular vasoconstrictor
coupling during the ischemic depolarization which con-
tributes to the hemodynamic progression of damage in
focal cerebral ischemia [5]. They suggest that by reducing
the adverse vascular effects of tissue depolarization is a
possible way the neuroprotective drugs act to reduce the
tissue injury.
We have observed a rapid transcriptional upregulation of
contractile endothelin-1 (ETB receptors), and angiotensin
II AT1 receptors in vascular smooth muscle cells in the
middle cerebral artery (MCA) leading to the ischemic
region starting immediately after induction of the cerebral
ischemia [6,7]. These changes result in enhanced contrac-
tion of the vasculature leading to the ischemic region, par-
ticularly because agonists for these receptor are produced
in the cerebrovascular endothelium [8]. In agreement, sin-
gle receptor inhibition has in the past only been found to
have limited effect in reducing cerebral infarct size after
focal ischemia [3]. Therefore, we hypothesize that block-
ing the transcriptional upregulation of endothelin, serot-
onin and angiotensin receptors would reduce the cerebral
infarct that occurs after focal cerebral ischemia.
To test this hypothesis, an animal model of consistently
inducible cerebral ischemia was used: 2 hours reversible
middle cerebral artery occlusion (MCAO) followed by
reperfusion for 48 hours [9]. We present the novel obser-
vations that there is upregulation of the mitogen-activated
protein kinase (MAPK) extracellular signal-regulated
kinase (ERK1/2), the transcription factor Elk-1, and the
contractile receptors for endothelin (ETA and ETB), angi-
otensin II AT1, and 5-hydroxytryptamine 5-HT1B receptors
in both the MCA leading to the ischemic region and in
microvessels within the infarct area but not in adjacent
brain tissue. Systemic treatment with the MEK1 inhibitor
U0126, given at the start of the reperfusion or at 6 hours
afterwards abolished the enhanced receptor protein
expression and reduced the infarct volume.
Results
Signal transduction after MCA occlusion
Distal MCAO resulted in an abrupt decrease in CBF over
the dorsolateral cortex; flow was reduced to 15 ± 3% of the
baseline flow in the ischemic region. After 2 hours the
block was removed. The flow subsequently returned to
baseline. The animal were carefully monitored during the
following 48 hours and then sacrificed. We calculated the
neurology score (MCAO: 4.0 ± 0.5, P < 0.05 versus sham
operated animals) (Table 1), collected tissue for immu-
nostaining and Western blot, and determination of the
infarct volume (24.8 ± 1.4% of total cerebrum) and the
degree of edema (Fig. 1 and 2). The physiological param-
eters did not differ between the groups (Table 2). There
was an increase in body temperature after MCAO in all
groups which are in agreement with previous studies [10];
this did not differ between the different groups in our
study.
We subsequently assessed if MCAO leads to activation of
pERK1/2 and pElk-1 in the smooth muscle cells of the
MCA, the associated microvessels, and in brain tissue.
There was weak staining of both in vehicle control (Fig.
3). The results showed that pERK1/2 and pElk-1 were
markedly activated at 48 hours after the MCAO + vehicle
(Fig. 3). The pERK1/2 and pElk-1 immunoreactivity were
localized in the cytoplasm of the smooth muscle cells as
verified by co-localization experiments with smooth mus-
cle specific actin (Fig. 5). As can be seen in the illustration
there was a significant enhanced expression of pERK1/2
(185 ± 11 %) and pElk-1 (174 ± 6 %) in the MCA leading
to the infarct and in associated microvessels (130 ± 10 %
and 130 ± 6 %, respectively) (Fig. 4). However, there was
no significant change in their expression in associated
brain tissue (106 ± 3 % and 117 ± 13 %, respectively) or
in other regions of the brain. There was a weak expression
of pElk-1 in cell bodies within the brain tissue around the
MCA.
Inhibition of signal-transduction
Administration of the MEK1-specific inhibitor U0126 (30
mg/kg, intraperitoneal), which blocks the enzymatic
activity of MEK1 [11] reduced both the infarct volume and
the neurology score when given in conjunction with the
start of the reperfusion (0 hour) or at 6 hours after the
MCAO; the reductions were significant for infarct volume
Table 1: Neurological Scores measured at 0, 24 and 48 hours after MCA occlusion using an established scoring scale [26].
Neurology score Control
(n = 7)
U0126 – 0 h
(n = 7)
U0126 – 6 h
(n = 6)
U0126 – 12 h
(n = 6)
0 h 4 ± 0.0 4± 0.0 4 ± 0.0 4 ± 0.0
24 h 3.8 ± 3.4 3 ± 0.6 3.5 ± 0.5 3.8 ± 0.3
48 h 4 ± 0.5 2 ± 0.7 3.3 ± 0.7 3.8 ± 0.3
Comparison between the U0126 treated groups and vehicle treated rats (control). Data are expressed as mean ± S.D and n = number of rats.Page 2 of 13
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0.05; Fig. 1 and 2A), and neurology score (2 ± 0.7 and 3.3
± 0.7; respectively, P < 0.05) but not for the edema (Table
1) (Fig. 2B). The administration of U0126 with start at 12
hours after the initiation of reperfusion did not result in a
significantly diminished infarct volume (20.3 ± 1 % of
cerebrum; Fig. 2A) or the neurology score (3.8 ± 0.3; Table
1).
We subsequently assessed if MEK1 inhibition altered the
cerebrovascular activation of pERK1/2 and pElk-1 in the
vascular smooth muscle cells after MCAO. The results
showed that systemic treatment with U0126 abolished
the increase in pERK1/2 and pElk-1 activation after
MCAO when the treatment was given in conjunction with
reperfusion (0 hour) or with start 6 hours, and for pERK1/
2 12 hours after the start of the reperfusion (Fig. 3 and 4).
In the contralateral hemisphere there was only weak
pERK1/2 and pElk-1 activity at baseline in the vasculature,
and this was not affected by MCAO (Fig. 3); the levels of
activity were comparable to those of the vehicle control.
There was no significant change in brain tissue for pERK1/
2 and pELK-1 activity (Fig. 3).
Cerebrovascular receptor expression
To investigate whether the MAPK activity leads to changes
in receptor protein transcription, we analyzed the expres-
sion of vascular receptors using immunostaining and
image analysis with confocal microscopy. We observed for
the first time a significant increase in the expression of
endothelin ETB, angiotensin AT1, and 5-hydroxytryp-
tamine 5-HT1B receptors in smooth muscle cells not only
in the ischemic MCA but also in smooth muscle cells of
cerebral microvessels associated with the ischemic region
(Fig. 6 and 7). There were no changes in receptor expres-
sion in contralateral vessels. Importantly, the endothelin
ETA receptor expression was unchanged after MCAO and
following treatment at all locations (Fig. 6 and 7). Double
immunostaining for endothelin ETB, angiotensin AT1, and
5-hydroxytryptamine 5-HT1B receptors versus smooth
muscle actin, expressed in the smooth muscle cells,
revealed clear co-localization. All three receptors co-local-
ized with the smooth muscle cells, in addition, endothe-
lin ETB receptor protein was located in the endothelial
cells of the cerebral vessels (Fig. 8); previous studies with
the endothelial marker CD31 has verified this in cerebral
arteries [12]. MCAO did however not show enhanced (or
altered) expression of the endothelial ETB receptors.
Systemic treatment with the MEK1 inhibitor abolished
the increase in receptor expression in both vascular
regions when treatment was initiated either at reperfusion
(0 hour) or 6 hours afterwards but not when starting 12
hours after reperfusion (Fig. 6); this correlates well with
the reduction in infarct volume at the same time points
(Fig. 1 and 2A).
Western blot
The Western blot experiments showed a significant
increase in ETB protein level after MCAO as compare to the
vehicle group (122 ± 9 %; p < 0.05). Treatment with the
MEK inhibitor (U0126) given in conjunction with reper-
fusion (0 hour) prevented the increase in the ETB receptor
protein (101 ± 5%) (Fig. 9).
Discussion and conclusion
We have observed that acute cerebral infarction followed
by reperfusion in the rat is accompanied by upregulation
of the functional contractile phenotype and the mRNA
expression of endothelin ETB and angiotensin AT1 recep-
tors [6,7]. In the present study we show for the first time
that the proteins of the contractile receptors ETB, AT1 and
5-HT1B receptors are upregulated in the smooth muscle
cells of the MCA leading to the ischemic region and in
microvessels associated with the focal ischemia. The co-
localization studies verified that the enhanced expression
is located in the smooth muscle cells. We have previously
shown with confocal microscopy and double immunos-
taining that the enhanced receptor expression is localized
to the smooth muscle cells (co-localize with smooth mus-









pO2 (mmHg) 97.2 ± 2 108.3 ± 3.2 107.6 ± 7 120.4 ± 10
pCO2(mmHg) 52.6 ± 3 50.6 ± 1.9 49.6 ± 4.5 48.5 ± 0.6
pH 7.3 ± 0.01 7.3 ± 0.01 7.3 ± 0.02 7.5 ± 0.01
Plasma glucose (mmol/L) 12.1 ± 0.4 10.2 ± 0.6 11.1 ± 0.3 10.7 ± 0.4
MAP (mmHg) 91.1 ± 2.2 92.6 ± 1.8 91.8 ± 2.5 101.4 ± 4.7
Temperature during operation (°C) 37.1 ± 0.2 37.2 ± 0.1 37.2 ± 0.1 37.3 ± 0.2
Temperature before reperfusion (°C) 39.3 ± 0.1 39.2 ± 0.1 39.3 ± 0.2 38.9 ± 0.2
Temperature after reperfusion (°C) 38.1 ± 0.1 38.6 ± 0.3 38.1 ± 0.1 38.6 ± 0.2
Weight loss 48 h after occlusion (%) 13.4 ± 1.3 8.0 ± 1.8 16.1 ± 3.2 10.3 ± 2.4
Values are the mean % of control ± s.e.m., P > 0.05 between the groups, n = number of rats.Page 3 of 13
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(with CD31 staining) in conjunction with experimental
subarachnoid hemorrhage [12]. The enhance receptor
expression was verified by Western blot of the ETB receptor
protein.
This upregulation was associated with activation of the
signal transduction proteins pERK1/2 and the transcrip-
tion factor pElk-1. Administration of the MEK1 inhibitor
U0126, acting upstream of ERK1/2, abolished their activa-
tion as well as the enhanced receptor expression, and
reduced the infarct volume. Importantly this reversal
worked if U0126 was given both immediately following
the reperfusion (0 hour) and at 6 hours after the insult. If
the MEK1 inhibitor was given 12 hours after the start of
the reperfusion there were no significant changes in inf-
arct volume, neurology score or receptor expression but
still the MAPK pERK1/2 and the transcription factor pElk-
1 levels were depressed. The reduction in infarct volume
occurred in concert with a reduction in receptor expres-
sion and activation of ERK1/2 and Elk-1 in the middle cer-
ebral artery and in microvessels on the ischemic side of
the brain. This agrees with a previous study that showed a
transient (within the first hours) increase in the MEK/ERK
Typical examples of coronal brain sections that show smaller ischemic areas in animals treated with U0126 immediately after re erfusion aft r MCAO (0 h), or given at 6 and 12 hours after MCAO and 48-h reperfusion versus animals treated with v hi-cle (A)Figu e 1
Typical examples of coronal brain sections that show smaller ischemic areas in animals treated with U0126 immediately after 
reperfusion after MCAO (0 h), or given at 6 and 12 hours after MCAO and 48-h reperfusion versus animals treated with vehi-
cle (A).Page 4 of 13
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A: Measurements of the brain damage (% of total volume) showed a significant Decrease in infarct size on the ischemic side in animals treated with U0126 starting at 0 h (11.8 ± 2 %**) and 6 h (14.6 ± 3 %*) aft r MCAO as compared to the ontrol group(24.8 ± 2 %) and trea ed after 12 h (20.3 ±  %)(*P < 0.05 ** P < 0.01)Figure
A: Measurements of the brain damage (% of total volume) showed a significant. Decrease in infarct size on the ischemic side in 
animals treated with U0126 starting at 0 h (11.8 ± 2 %**) and 6 h (14.6 ± 3 %*) after MCAO as compared to the control group 
(24.8 ± 2 %) and treated after 12 h (20.3 ± 1 %)(*P < 0.05 ** P < 0.01). B: Analysis of the edema (% of total brain volume) 
showing no significant change in the U0126 treated groups (0 h; 1.05 ± 0.02, 6 h; 0.98 ± 0.02 and 12 h; 1.02 ± 0.04) with the 
control rats (1.01 ± 0.03). Values are the mean ± s. e. m. and n = 6–7.
Immunofluorescence staining for pERK1/2, and transcription factor pELK-1 in the ischemic middle cerebral artery (MCA), cer-ebral microv ssels (Mic.V), and surrounding brain ti sue (Brain) in rats treated with vehicle, MCAO + vehicle, o  MCAO plus U0126 at diff rent time pointsFigure 3
Immunofluorescence staining for pERK1/2, and transcription factor pELK-1 in the ischemic middle cerebral artery (MCA), cer-
ebral microvessels (Mic.V), and surrounding brain tissue (Brain) in rats treated with vehicle, MCAO + vehicle, or MCAO plus 
U0126 at different time points. There was an increase in activated (phosphorylation = p) ERK1/2 and ELK-1 in the smooth 
muscle cell layer of ischemic vessels (MCA and Mic.V) as compared to vehicle. Treatment with U0126 starting at 0 h, 6 h and 
12 h after occlusion prevented the increase in expression of pERK1/2 in smooth muscle cells of the MCA and Mic.V as studied 
at 48 h. Data were obtained with confocal microscopy. Scale bar, 50 μm.
BMC Neuroscience 2008, 9:85 http://www.biomedcentral.com/1471-2202/9/85pathway located to neurons and astrocytes in conjunction
with focal ischemia (but not studied before in cerebral
vasculature); systemic administration of U0126 inhibited
this response [13]. We suggest that the MEK/ERK pathway
participates as a switch-on mechanism for the receptor
upregulation and the associated brain damage. In sup-
port, we found in a Western blot time study of global
ischemia that there was early activation of this pathway
already within one hour [14]. In addition, there was no
activation of c-jun N-terminal kinase (JNK) or p38 at time
points before 24 hours [14]. The MEK/ERK pathway uses
several transcription factors, the pElk-1 studied here can
be regarded as an example of one of those. We suggest that
there is a "switch-on" mechanism that is accessible to
early antagonism but if therapy is give after this (as at 12
hours after reperfusion) it will be too late to modify the
outcome.
One might suggest that another way to reduce the infarct
would be to use specific endothelin-receptor [15] or angi-
otensin-receptor antagonists [16]; there are data to pro-
vide support for such a concept. Dual blockade of the AT1
and ETA receptors produced stronger reduction in infarct
than single receptor blockade; this is due to upregulation
of several receptor subtypes after MCAO [17]. We have in
this study demonstrated that multiple receptor subtypes
are upregulated in the vasculature following the ischemia
(at least 3 subtypes as shown in this study); we propose
that blockade at the transcriptional/translation level is a
superior approach to specific receptor antagonism and
avoids significant systemic effects and at the same time
modulates the enhanced expression of several receptors.
It is intriguing that U0126 does not affect phosphoryla-
tion of p38 or JNK in cultured neurons [18], in vivo in
brain tissue [13] or in cerebrovascular smooth muscle
cells [14]. These findings enable us to exclude the possibil-
ity that U0126 reduced the infarct volume by nonspecific
inhibition of pro apoptotic mechanisms. In addition,
U0126 increases phosphorylation of MEK1/2 in cortical
neurons; hence, U0126 does not affect upstream compo-
nents of MEK1/2 [19]. Thus, it is reasonable to assume
that the effect of U0126 is due to inhibition of cerebrov-
ascular MEK1 activity. Treatment with U0126 abolished
the increase in receptor expression both in the MCA and
in microvessels without affecting activity in contralateral
blood vessels or in the adjacent brain tissue. This is con-
sistent with previous reports that administration of
U0126 in conjunction with MCAO decreases pERK1/2
immunoreactivity in the ischemic brain region of the
mouse [18] and rat [20]. In the mouse study, 3-h MCAO
was followed by reperfusion for 24 h, but U0126 reduced
the infarct volume only when administered in conjunc-
tion with MCAO [18]. Another selective MEK1 inhibitor
PD98059 failed to protect ischemic cell death in the CA1
region in the gerbil [21]. It revealed however a neuropro-
tective effect when given intracerebroventricular [22]. The
MEK1 inhibitor SL327 reduced infarct size and improved
neurological function after ischemic injury in mice [23].
The differences between the studies may be due to dose
administered, the experimental model used for cerebral
ischemia, and the ability of the drug to penetrate across
the blood-brain barrier [13]. Here we show for the first
time that U0126 is effective in a clinically relevant time
frame. It was effective not only when given in conjunction
A and B: Bar graph demonstrating the fluorescence intensity for pERK1/2, and pElk-1 in the MCA and micro-vesselsFigure 4
A and B: Bar graph demonstrating the fluorescence intensity for pERK1/2, and pElk-1 in the MCA and micro-vessels. There 
was a significant increase of pERK1/2, and pElk-1 protein expression in MCAO as compared to control. This was prevented 
with U0126 treatment starting at 0 h and 6 h but not 12 h. Results are presented as the mean percentage relative to control ± 
s.e.m.; n = 5. *P < 0.05 significant difference between control groups and MCAO, § < 0.05 significant difference between 
MCAO and treated groups.Page 6 of 13
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repeated at 24 h. In agreement with these observations,
ERK1/2 inhibition does not alter cortical blood flow or
alters the vessel tone in the first hour of its administration
[18,24]. Hence, it is not acting through a direct vasodila-
tor mechanism or acts acutely to interact with excitation-
contraction coupling in the smooth muscle cells. Quanti-
tative studies of regional cerebral blood flow have
revealed that flow during the first hours after start of reper-
fusion returns to near normal levels but still there is the
appearance of marked cell death putatively due to meta-
bolic dysfunction [9]. The present data suggest that a vas-
cular component might contribute to the development of
tissue damage.
Our observations are in agreement with the diminished
activity of the downstream MAPK MEK/ERK pathway and
its transcription factor Elk-1, as well as the reduced expres-
sion of specific vascular receptor proteins both in large
cerebral vessels and in microvessels. In functional studies
there is reduced contraction following specific ETB and
AT1 receptor stimulation [[6,7], and [20]]. Inhibition of
this sequence of events is accompanied by reduction of
neuronal death and improvement in neurology score in
the same animal and agrees well with recent data on
experimental subarachnoid hemorrhage[25].
We suggest that more focus should be directed towards
the cerebral vasculature. Although the MEK/ERK pathway
plays a crucial role in brain injury after ischemia and
reperfusion, we provide here the first direct evidence of an
associated vascular mechanism, involving both large cere-
bral arteries and brain microvessels. This may provide a
novel way to search for agents that will alleviate brain
injury following cerebral ischemia.
Double immunofluorescence staining for pERK1/2, pElk-1 and actin in smooth muscle cells in the middle cerebral artery after MCAOFig r 5
Double immunofluorescence staining for pERK1/2, pElk-1 and actin in smooth muscle cells in the middle cerebral artery after 
MCAO. (A) Localization of pERK1/2 immunoreactivity, (B) actin immunostaining, and (C) their co-localization in the smooth 
muscle cells. (D) The pElk-1 immunoreaction, (E) the actin immunostaining, and (F) their co-localization in the smooth muscle 
cells. The scale bar represents 50 μm.Page 7 of 13
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Middle cerebral artery occlusion
Male Wistar-Hanover rats (Møllegaard Breeding Centre,
Copenhagen, Denmark) weighing approximately 300–
350 g were used. Experimental procedures were approved
by the Lund University Animal Ethics Committee (M43-
07). The animals were initially anaesthetized using 4 %
halothane in N2O:O2 (70 %:30 %). Thereafter the rats
were kept anaesthetized through a mask with 2 – 2.5 %
halothane during the operation. To confirm a proper
occlusion of the proximal middle cerebral artery (MCA), a
laser Doppler probe (Perimed, Järfälla, Sweden) was fixed
on the skull (1 mm posterior to bregma and 6 mm from
the midline of the right side), measuring regional cortical
blood flow. A polyethylene catheter was inserted into a
tail artery for measurement of mean arterial blood pres-
sure (MAP), pH, pO2, pCO2, and plasma glucose. A rectal
temperature probe connected to a homeothermal blanket
was used to maintain body temperature at 37°C during
the operational procedure.
Immunofluorescence staining for 5-HT1B, (A-E), AT1(F-J), ETB (K-O), and ETA (P-T) receptors in the ischemic middle cerebral artery (MCA), rebral microvessels (Mic.V), and surrounding brain tissue (Brain)Figure 6
Immunofluorescence staining for 5-HT1B, (A-E), AT1(F-J), ETB (K-O), and ETA (P-T) receptors in the ischemic middle cerebral 
artery (MCA), cerebral microvessels (Mic.V), and surrounding brain tissue (Brain). There was a clear increase in 5-HT1B, AT1, 
and ETB receptor protein levels in the smooth muscle cell layer of ischemic vessels (MCA and Mic.V) as compared to vehicle 
control. Treatment with U0126 starting at 6 h after MCAO prevented the increase in expression of 5-HT1B, AT1 and ETB 
receptors in smooth muscle cells of the MCA and Mic.V but not at 12 h. The ETA receptor is normally expressed fairly strong, 
and expression is not upregulated in ischemia. U0126 treatment did not change the expression of ETA receptor protein in the 
smooth muscle cell layer. There was no significant difference in expression of receptor protein levels in control brain tissue, in 
ischemic brain tissue, and tissue from animals treated with U0126. Data were obtained with confocal microscopy. Scale bar, 50 
μm.Page 8 of 13
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transient MCAO as outlined before [9]. Briefly, an inci-
sion was made in the midline of the neck, and the right
common, external, and internal carotid arteries were
exposed. The common and external carotid arteries were
permanently ligated by sutures. A filament was inserted
into the internal carotid artery via an incision in the com-
mon carotid artery and further advanced until the
rounded tip reached the entrance of the right MCA. The
resulting occlusion was visible by laser-Doppler as an
abrupt reduction of cerebral blood flow of approximately
80–90 %. The anesthesia was then discontinued and the
animals allowed recovering.
Two hours after the occlusion, the rat was re-anesthetized
to allow for withdrawal of the filament and subsequent
reperfusion. In conjunction with the reperfusion (0 h), at
6 h or at 12 h afterwards, and at 24 h after the start of the
reperfusion in the same animal, the rats were injected
intraperitoneal with 30 mg/kg U0126 dissolved in
dimethylsulfoxide (DMSO) while control groups received
the same volume of vehicle (DMSO). In preliminary
experiments we evaluated U0126 doses varying between
10 mg/kg and 100 mg/kg (n = 3–6) (unpublished data);
30 mg/kg was the lowest that elicited a clear significant
effect on infarct volume. Control rats were injected with
an equal volume of DMSO at the same time points. The
rats were neurologically examined immediately before
sacrifice according to an established system [26]. For
details of the neurology scale see [20]. Forty-eight hours
after MCAO, rats were anesthetized and decapitated; the
brain was removed and placed in cold buffer solution. The
right and left MCAs and associated brain tissue were dis-
sected, snap frozen in cold isopentane, and maintained at
-80°C for further examination with immunohistochemis-
try.
The specificity of U0126 has been tested in numerous
studies previously [13,18] on isolated cells and in vivo; we
have performed this on cerebral blood vessels with and
without the MEK1 inhibitor [20,27]. In addition, MCAO
and organ culture elicited an early increase in the pERK1/
2 activity but not in pP38 or in pJNK [28].
Evaluation of brain damage and edema
Brains were sliced coronal into 2-mm thick sections and
stained by 1% 2, 3, 5-triphenyltetrazolium chloride dis-
solved in buffer solution at 37°C for 20 min. The size of
ischemic brain damage and the degree of edema (swelling
of the right part of the brain relative to the left contra lat-
eral side) were calculated as a percentage of the total brain
volume using the software program Brain Damage Calcu-
lator 1.1 (MB Teknikkonsult, Lund, Sweden).
Neurological examination
The animals were examined neurologically before recircu-
lation and immediately before they were sacrificed, 48
hours after MCAO according to an established scoring sys-
tem [26,29].
A and B: Bar graph demonstrating the fluorescence intensity for 5-HT1B, AT1, ETB and ETA receptors in the middle cerebral artery and micro-vess lsFigure 7
A and B: Bar graph demonstrating the fluorescence intensity for 5-HT1B, AT1, ETB and ETA receptors in the middle cerebral 
artery and micro-vessels. There was a significant increase of 5-HT1B, AT1, and ETB protein expression in MCAO as compared 
to control. This was prevented with U0126 treatment starting at 0 h and 6 h in the MCA and in the micro-vessels but not 12 h. 
Results are presented as the mean percentage relative to control ± s.e.m.; n = 5. *P < 0.05, **P < 0.01. Statistically significant 
differences between the groups are shown; §< 0.05, §§ < 0.01 significant difference between MCAO and treated groups.Page 9 of 13
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BMC Neuroscience 2008, 9:85 http://www.biomedcentral.com/1471-2202/9/85Immunostaining
For immunostaining, the middle cerebral artery and the
surrounding brain tissue were dissected, placed on Tissue
TEK (Gibo, Invitrogen A/S, Taastrup, Denmark), and fro-
zen on dry ice [17]. Thereafter, they were sectioned into 10
μm-thick slices. Cryostat sections of the arteries and tissue
were fixed for 10 min in ice-cold acetone (-20°C) and
rehydrated in PBST (phosphate buffer solution containing
0.3% Triton X-100) for 15 min at room temperature. The
tissues were then permeabilized and blocked for 1 h in
blocking solution containing PBS, 0.3% TritonX-100, 1%
bovine serum albumin (BSA), and 5% normal donkey
serum to ensure antibody specificity. They were incubated
overnight at 4°C with primary antibodies: rabbit antihu-
man ETB (Abcam, ab1921) 1:400, rabbit antihuman AT1
(Santa Cruz, sc-1173), goat antihuman 5-HT1B (Santa
Co-localization of the immunofluorescence for 5-HT1B (A, C), AT1 (D, F) and ETB (G, I) receptor proteins and smooth muscle cell actin (B, E, H) in the MCA after MCAOFigure 8
Co-localization of the immunofluorescence for 5-HT1B (A, C), AT1 (D, F) and ETB (G, I) receptor proteins and smooth muscle 
cell actin (B, E, H) in the MCA after MCAO. Their co-localization is depicted in the merged pictures to the right (C, F, I). Scale 
bar, 50 μm.Page 10 of 13
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21194) 1:100, rabbit antiphospho ERK 1/2 MAPK (Cell-
signaling #4376) 1:50, and rabbit anti phospho Elk-1
(Cellsignaling #9181) 1:50 (diluted in PBS containing
0.3% Triton X-100, 1% BSA, and 2% normal donkey
serum). Sections were subsequently incubated for 1 h at
room temperature with secondary antibodies: Cy™2-con-
jugated donkey anti rabbit (JacksonImmunoResearch,
711-165-152) and Cy™2-conjugated donkey anti goat
(JacksonImmunoResearch, 705-225-003) diluted 1:200
in PBS containing 0.3% Triton X-100 and 1% BSA. The
sections were washed with PBS and mounted with Perma-
fluor mounting medium (Beckman Coulter, PN IM0752).
Immunoreactivity was visualized and photographed with
a Nikon confocal microscope (EZ-c1, German) at the
appropriate wavelength. The same procedure was used for
the negative controls, but primary antibodies were omit-
ted. The fluorescence intensity was measured with the
software image J http://rsb.info.nih.gov/ij/ The fluores-
cence was measured in 4–6 areas in each tissue (in a
blinded fashion), and the mean value was used.
Double immunostaining
Double immunostaining was done for endothelin ETB,
angiotensin AT1, and 5-hydroxytryptamine 5-HT1B recep-
tor protein, and phosphorylated ERK1/2 and Elk-1 pro-
teins versus smooth muscle actin, expressed in the smooth
muscle cells. The same antibodies were used as above but
in addition mouse anti rat smooth muscle actin antibod-
ies (Santa Crus, SC-53015) 1:200, diluted in PBS contain-
ing 0.3 % Triton X-100, 1 % BSA and 2 % normal donkey
serum. The secondary antibodies used were donkey α-rab-
bit Cy™2- (JacksonImmunoResearch,) 1:200, donkey α-
goat Cy™2- (Jacksson,) 1:200 and donkey α-mouse Texas
Red (JacksonImmunoResearch,) 1:250 diluted in PBS
containing 3 % Triton X-100 and 1 % BSA. The antibodies
were then detected at the appropriate wave lengths in a
confocal microscope (EZ-cl, Germany).
Western blot experiments
The proximal MCA segments (n = 12 in each group) were
harvested and frozen in liquid nitrogen and homogenized
in cell extract denaturing buffer (BioSource, USA) with
addition of a phosphates inhibitor cocktail and protease
inhibitor cocktail (Sigma, USA). Whole cell lysates were
Expression and upregulation of ETB protein levels in middle cerebral artery after 48 h of MCAO with β-actin as a loading con-trol is hown aboveFigure 9
Expression and upregulation of ETB protein levels in middle cerebral artery after 48 h of MCAO with β-actin as a loading con-
trol is shown above. Treatment with U0126 decreased the enhanced expression of ETB receptor protein after MCAO. Data is 
expressed as mean ± s.e.m., n = 4, *P < 0.05.Page 11 of 13
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4°C for 30 min, and the supernatants were collected as
protein samples. The Protein concentrations were deter-
mined using the protein assay reagents (Bio-Rad, Her-
cules, CA, USA) and stored at -80°C until
immunoblotting assay. The protein homogenates were
diluted 1:1 (v/v) with 2 × SDS sample buffer (Bio-Rad).
25–50 μg of total proteins were boiled for 10 min in SDS
sample buffer and separated by 4–15 % SDS Ready Gel
Precast Gels (Bio-Rad, USA) for 120 min at 100 v, and
transferred electrophoretically to nitrocellulose mem-
branes (Bio-Rad) at 100 v for 60 min. The Membrane was
then blocked for 1 h at room temperature with phosphate
buffered saline (PBS) containing 0.1 % Tween-20 (Sigma)
and 5 % non-fat dried milk, and incubated with primary
antibody, Rabbit polyclonal to endothelin B receptor (ab
1921), diluted 1:200 overnight at 4°C, followed by incu-
bation with anti-rabbit IgG, horseradish peroxidase
(HRP)-conjugated secondary antibodies (Amersham Bio-
sciences, Piscataway, NJ, USA) diluted 1: 5000–10.000 for
1 h at room temperature. The probed proteins were devel-
oped by .LumiSensor Chemiluminescent HRP Substrate
kit (GenScript Corp., Piscataway, NJ, USA). To detect mul-
tiple signals using a single membrane, the membrane was
incubated for 5–15 min at room temperature with restore
plus Western blot stripping buffer (Pierce Biotechnology,
Inc., Rockford, IL. USA). The membranes were visualized
using a Fujifilm LAS-1000 Luminiscent Image Analyzer
(Stamford, CT, USA.). The quantification of band inten-
sity was analyzed with Image Gauge Ver. 4.0 (Fuji Photo
Film Co., LTD., Japan). Three independent experiments
were performed in duplicate.
Statistical analysis
Data are expressed as the mean ± s.e.m. Statistical analyses
were performed using the nonparametric Kruskal-Wallis
test with Dunn's post hoc test for quantitative immuno-
histochemistry and one-way ANOVA analysis of variance
with Dunnett's test for infarct and edema brain evalua-
tion. For Western blot comparisons between two groups
were performed using two-tailed unpaired Student's t-test
and at least 3 different samples or independent experi-
ments were analyzed in each group. P-values less than
0.05 were considered significant, n = number of rats.
Authors' contributions
AM carried out the experiments, participated in design,
statistical analysis and writing of the manuscript. LE con-
ceived of the study, participated in its design, coordina-
tion and writing. All authors read and approved the final
manuscript.
Acknowledgements
Supported by Swedish Research Council (grant no 5958), Heart -Lung foun-
dation, and Lundbeck foundation (LUCENS), Denmark.
References
1. Hossmann KA: Periinfarct depolarizations.  Cerebrovasc Brain
Metab Rev 1996, 8(3):195-208.
2. Hossmann KA: Viability thresholds and the penumbra of focal
ischemia.  Ann Neurol 1994, 36(4):557-565.
3. Dirnagl U: Bench to bedside: the quest for quality in experi-
mental stroke research.  J Cereb Blood Flow Metab 2006,
26(12):1465-1478.
4. Back T, Kohno K, Hossmann KA: Cortical negative DC deflec-
tions following middle cerebral artery occlusion and KCl-
induced spreading depression: effect on blood flow, tissue
oxygenation, and electroencephalogram.  J Cereb Blood Flow
Metab 1994, 14(1):12-19.
5. Shin HK, Dunn AK, Jones PB, Boas DA, Moskowitz MA, Ayata C:
Vasoconstrictive neurovascular coupling during focal
ischemic depolarizations.  J Cereb Blood Flow Metab 2006,
26(8):1018-1030.
6. Stenman E, Malmsjo M, Uddman E, Gido G, Wieloch T, Edvinsson L:
Cerebral ischemia upregulates vascular endothelin ET(B)
receptors in rat.  Stroke 2002, 33(9):2311-2316.
7. Stenman E, Edvinsson L: Cerebral ischemia enhances vascular
angiotensin AT1 receptor-mediated contraction in rats.
Stroke 2004, 35(4):970-974.
8. Loesch A, Burnstock G: The endothelium: electron-immunocy-
tochemistry of vasoactive agents.  In Modern Visualisation of the
Endothelium Edited by: Polak JM. Amsterdam: Harwood Academic
Publishers; 1998:3-44. 
9. Memezawa H, Minamisawa H, Smith ML, Siesjo BK: Ischemic
penumbra in a model of reversible middle cerebral artery
occlusion in the rat.  Exp Brain Res 1992, 89(1):67-78.
10. Zhao Q, Memezawa H, Smith ML, Siesjo BK: Hyperthermia com-
plicates middle cerebral artery occlusion induced by an
intraluminal filament.  Brain Res 1994, 649(1–2):253-259.
11. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser
WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al.: Identification
of a novel inhibitor of mitogen-activated protein kinase
kinase.  J Biol Chem 1998, 273(29):18623-18632.
12. Beg SS, Hansen-Schwartz JA, Vikman PJ, Xu CB, Edvinsson LI: Pro-
tein kinase C inhibition prevents upregulation of vascular
ET(B) and 5-HT(1B) receptors and reverses cerebral blood
flow reduction after subarachnoid haemorrhage in rats.  J
Cereb Blood Flow Metab 2007, 27(1):21-32.
13. Wang ZQ, Wu DC, Huang FP, Yang GY: Inhibition of MEK/ERK 1/
2 pathway reduces pro-inflammatory cytokine interleukin-1
expression in focal cerebral ischemia.  Brain Res 2004,
996(1):55-66.
14. Ansar S, Edvinsson L: Subtype activation and interaction of pro-
tein kinase C and mitogen-activated protein kinase control-
ling receptor expression in cerebral arteries and
microvessels after subarachnoid hemorrhage.  Stroke 2008,
39(1):185-190.
15. Patel TR, Galbraith SL, McAuley MA, Doherty AM, Graham DI,
McCulloch J: Therapeutic potential of endothelin receptor
antagonists in experimental stroke.  J Cardiovasc Pharmacol 1995,
26(Suppl 3):S412-415.
16. Nishimura Y, Ito T, Saavedra JM: Angiotensin II AT(1) blockade
normalizes cerebrovascular autoregulation and reduces cer-
ebral ischemia in spontaneously hypertensive rats.  Stroke
2000, 31(10):2478-2486.
17. Stenman E, Jamali R, Henriksson M, Maddahi A, Edvinsson L: Coop-
erative effect of angiotensin AT(1) and endothelin ET(A)
receptor antagonism limits the brain damage after ischemic
stroke in rat.  Eur J Pharmacol 2007, 570:142-148.
18. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K,
Moskowitz MA, Bonventre JV, Alessandrini A: Intravenous admin-
istration of MEK inhibitor U0126 affords brain protection
against forebrain ischemia and focal cerebral ischemia.  Proc
Natl Acad Sci USA 2001, 98(20):11569-11574.
19. Yun HY, Gonzalez-Zulueta M, Dawson VL, Dawson TM: Nitric
oxide mediates N-methyl-D-aspartate receptor-induced
activation of p21ras.  Proc Natl Acad Sci USA 1998,
95(10):5773-5778.
20. Henriksson M, Stenman E, Vikman P, Edvinsson L: MEK1/2 inhibi-
tion attenuates vascular ETA and ETB receptor alterations
after cerebral ischaemia.  Exp Brain Res 2007, 178(4):470-476.Page 12 of 13
(page number not for citation purposes)
BMC Neuroscience 2008, 9:85 http://www.biomedcentral.com/1471-2202/9/85Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
21. Sugino T, Nozaki K, Takagi Y, Hattori I, Hashimoto N, Moriguchi T,
Nishida E: Activation of mitogen-activated protein kinases
after transient forebrain ischemia in gerbil hippocampus.  J
Neurosci 2000, 20(12):4506-4514.
22. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV: MEK1 pro-
tein kinase inhibition protects against damage resulting
from focal cerebral ischemia.  Proc Natl Acad Sci USA 1999,
96(22):12866-12869.
23. Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos
JM, Feuerstein GZ: Significant neuroprotection against
ischemic brain injury by inhibition of the MEK1 protein
kinase in mice: exploration of potential mechanism associ-
ated with apoptosis.  J Pharmacol Exp Ther 2003, 304(1):172-178.
24. Beg SA, Hansen-Schwartz JA, Vikman PJ, Xu CB, Edvinsson LI: ERK1/
2 inhibition attenuates cerebral blood flow reduction and
abolishes ET(B) and 5-HT(1B) receptor upregulation after
subarachnoid hemorrhage in rat.  J Cereb Blood Flow Metab 2006,
26(6):846-856.
25. Ansar S, Vikman P, Nielsen M, Edvinsson L: Cerebrovascular ETB,
5-HT1B and AT1 receptor upregulation correlates with
reduction in regional CBF after subarachnoid hemorrhage.
Am J Physiol Heart Circ Physiol 2007, 293(6):H3750-H3758.
26. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski
H: Rat middle cerebral artery occlusion: evaluation of the
model and development of a neurologic examination.  Stroke
1986, 17(3):472-476.
27. Henriksson M, Xu CB, Edvinsson L: Importance of ERK1/2 in
upregulation of endothelin type B receptors in cerebral
arteries.  Br J Pharmacol 2004, 142(7):1155-1161.
28. Vikman P, Ansar S, Henriksson M, Stenman E, Edvinsson L: Cerebral
ischemia induces transcription of inflammatory and extra-
cellular-matrix-related genes in rat cerebral arteries.  Exp
Brain Res 2007, 183:499-510.
29. Menzies SA, Hoff JT, Betz AL: Middle cerebral artery occlusion
in rats: a neurological and pathological evaluation of a repro-
ducible model.  Neurosurgery 1992, 31:100-106.Page 13 of 13
(page number not for citation purposes)
